Concern over “unprecedented” intervention into biologics market


Doctors could sidestep “onerous” prescribing obligations for the etanercept biosimilar Brenzys under new recommendations by the PBAC, which has flexed its differential prescribing powers for the first time. In May, the government outlined two new policies to drive the uptake of biosimilars to curb spending on biologic drugs like etanercept (Enbrel), which at $167 million ...


Already a member? Login to keep reading


OR
© 2017 the limbic